Clin2
NCT02498756Possibly a fitNot yet recruiting

Immune cell therapy for advanced melanoma

Melanoma

Treatments studied

Part of Cancer, Skin clinical trials.

This trial tests a type of immune cell therapy called cytokine-induced killer cells for people with advanced melanoma that has not responded to other treatments. It aims to see if these cells can help shrink or slow down the cancer.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
300 people
Ages
18 years to 80 years
Study type
Interventional

Who can take part

  • You must have been diagnosed with melanoma that has spread to other parts of the body (stage IV).
  • Your melanoma must have continued to grow or not respond to previous treatments.
  • You should be generally active and able to care for yourself (ECOG score 0 or 1).
  • Your blood albumin level (a protein that helps support your health) must be 3.0 or higher.
  • You must be at least 18 years old and not pregnant or breastfeeding.
  • Any brain lesions must have been treated and stable for at least one month (if present).

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT02621021Recruiting· Phase 2
Immune cell therapy for advanced melanoma

This trial tests a treatment that uses your own immune cells, called tumor-infiltrating lymphocytes (TILs), to fight melanoma. Some participants also get a drug called pembrolizumab. The goal is to see if this approach can shrink tumors.

Bethesda, Maryland
NCT07028008Not yet recruiting
Personalized immune cell therapy for advanced melanoma

This trial tests a treatment made from your own immune cells (called tumor-infiltrating lymphocytes). The cells are taken from a tumor sample, multiplied in a lab, and given back to you to help fight the cancer. It's for people with melanoma that has not responded to standard immunotherapy.

NCT06739226Not yet recruiting· Phase 1/Phase 2
Combination immunotherapy for advanced melanoma

This trial tests a combination of immunotherapy treatments for advanced melanoma that has not responded to standard therapy. The goal is to use your own immune cells to fight the cancer more effectively.

Shenzhen, Guangdong
NCT06240143Recruiting· Phase 1/Phase 2
Intradermal immunotherapy for high-risk stage II melanoma

This trial tests if injecting two immunotherapy drugs (ipilimumab and nivolumab) just under the skin can help prevent high-risk stage II melanoma from spreading. It is for people who have recently had a thick melanoma removed and have not yet had a sentinel node biopsy.

Amsterdam
NCT06212388Not yet recruiting· Early Phase 1
Immune cell therapy with interferon or PD-1 for melanoma

This trial tests a special type of immune cells (gamma-delta T cells) given with either interferon or a PD-1 inhibitor for people with stage III-IV melanoma that can be removed with surgery. The goal is to see if this combination helps the immune system fight the cancer and prevent it from coming back.

NCT06204991Recruiting· Phase 1
T-cell therapy for advanced melanoma

This trial tests a new treatment called ADP-TILIL7 for people with advanced melanoma. It uses your own immune cells (T-cells) that are taken from a tumor, multiplied in a lab, and then given back to you to fight the cancer. The goal is to see if this treatment is safe and works better than standard options.

Herlev

Hear when a new Melanoma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.